CA2622222A1 - Therapeutic pyrrolidines - Google Patents

Info

Publication number

CA2622222A1

CA2622222A1 CA002622222A CA2622222A CA2622222A1 CA 2622222 A1 CA2622222 A1 CA 2622222A1 CA 002622222 A CA002622222 A CA 002622222A CA 2622222 A CA2622222 A CA 2622222A CA 2622222 A1 CA2622222 A1 CA 2622222A1

Authority

CA

Canada

Prior art keywords

alkyl

biphenyl

pyrrolidine

ylmethoxy

group

Prior art date

2005-09-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000001225 therapeutic effect Effects 0.000 title description 3
• 150000003235 pyrrolidines Chemical class 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 141
• 150000003839 salts Chemical class 0.000 claims abstract description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 37
• 238000011282 treatment Methods 0.000 claims abstract description 28
• 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 17
• 208000004296 neuralgia Diseases 0.000 claims abstract description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
• 208000021722 neuropathic pain Diseases 0.000 claims abstract description 12
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 8
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 7
• 208000011688 Generalised anxiety disease Diseases 0.000 claims abstract description 6
• 208000029364 generalized anxiety disease Diseases 0.000 claims abstract description 6
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 5
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 5
• 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
• 238000000034 method Methods 0.000 claims description 29
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 21
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
• 125000001424 substituent group Chemical group 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
• 201000010099 disease Diseases 0.000 claims description 16
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
• 241000124008 Mammalia Species 0.000 claims description 14
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
• 208000020401 Depressive disease Diseases 0.000 claims description 9
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
• 229910052799 carbon Inorganic materials 0.000 claims description 7
• 125000005549 heteroarylene group Chemical group 0.000 claims description 7
• XBUBHMYDYOIPGD-AWEZNQCLSA-N (3s)-3-[[2-(2,4-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 XBUBHMYDYOIPGD-AWEZNQCLSA-N 0.000 claims description 6
• WCOVTUQVMUPPBA-UQKRIMTDSA-N (3s)-3-[[2-(2,4-difluorophenyl)phenyl]methoxy]pyrrolidine;hydrochloride Chemical compound Cl.FC1=CC(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 WCOVTUQVMUPPBA-UQKRIMTDSA-N 0.000 claims description 6
• 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 5
• 229910052739 hydrogen Inorganic materials 0.000 claims description 5
• 125000001624 naphthyl group Chemical group 0.000 claims description 4
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
• RBCHFMNWLAVRPO-INIZCTEOSA-N (3s)-3-[(2-phenylphenyl)methoxy]pyrrolidine Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1CO[C@H]1CCNC1 RBCHFMNWLAVRPO-INIZCTEOSA-N 0.000 claims description 3
• GYGMDXJUPWUIKS-ZDUSSCGKSA-N (3s)-3-[[2-(2,3-difluorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C(=C(F)C=CC=2)F)C=1CO[C@H]1CCNC1 GYGMDXJUPWUIKS-ZDUSSCGKSA-N 0.000 claims description 3
• ZJUXDISIBQHQIX-AWEZNQCLSA-N (3s)-3-[[2-(2,4-difluorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound FC1=CC(F)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 ZJUXDISIBQHQIX-AWEZNQCLSA-N 0.000 claims description 3
• OAQUTYQPGHBFRF-INIZCTEOSA-N (3s)-3-[[2-(4-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 OAQUTYQPGHBFRF-INIZCTEOSA-N 0.000 claims description 3
• QZDLXDGUELPWKB-KRWDZBQOSA-N (3s)-3-[[2-(4-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 QZDLXDGUELPWKB-KRWDZBQOSA-N 0.000 claims description 3
• BEPFSQFEFIYIMZ-AWEZNQCLSA-N (3s)-3-[[5-fluoro-2-(2-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C(=CC=CC=2)F)C=1CO[C@H]1CCNC1 BEPFSQFEFIYIMZ-AWEZNQCLSA-N 0.000 claims description 3
• 125000004957 naphthylene group Chemical group 0.000 claims description 3
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
• YVUZTTOQUJABBE-ZDUSSCGKSA-N (3s)-3-[[2-(2,3-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1F YVUZTTOQUJABBE-ZDUSSCGKSA-N 0.000 claims description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 6
• 208000035475 disorder Diseases 0.000 abstract description 21
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
• -1 3-pyrrolidinyl radical Chemical class 0.000 description 74
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
• 238000006243 chemical reaction Methods 0.000 description 65
• 235000019439 ethyl acetate Nutrition 0.000 description 56
• 125000004432 carbon atom Chemical group C* 0.000 description 54
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
• 239000000543 intermediate Substances 0.000 description 49
• 239000000203 mixture Substances 0.000 description 48
• 239000000243 solution Substances 0.000 description 47
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
• 238000005481 NMR spectroscopy Methods 0.000 description 45
• 125000000217 alkyl group Chemical group 0.000 description 45
• 208000002193 Pain Diseases 0.000 description 40
• 230000002829 reductive effect Effects 0.000 description 38
• 230000036407 pain Effects 0.000 description 35
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 32
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
• 125000005843 halogen group Chemical group 0.000 description 22
• 150000003254 radicals Chemical class 0.000 description 21
• 230000001404 mediated effect Effects 0.000 description 20
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
• 239000002253 acid Substances 0.000 description 18
• 125000001072 heteroaryl group Chemical group 0.000 description 18
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 17
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 17
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 17
• 229960002748 norepinephrine Drugs 0.000 description 17
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 17
• 238000003756 stirring Methods 0.000 description 17
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
• 239000003921 oil Substances 0.000 description 16
• 229940076279 serotonin Drugs 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• 125000003545 alkoxy group Chemical group 0.000 description 15
• 239000003814 drug Substances 0.000 description 14
• 239000012458 free base Substances 0.000 description 14
• 239000000377 silicon dioxide Substances 0.000 description 14
• 238000004587 chromatography analysis Methods 0.000 description 13
• 238000002360 preparation method Methods 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 125000006239 protecting group Chemical group 0.000 description 13
• 239000000725 suspension Substances 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• 206010033799 Paralysis Diseases 0.000 description 12
• 239000002585 base Substances 0.000 description 12
• 208000021090 palsy Diseases 0.000 description 12
• 239000002904 solvent Substances 0.000 description 12
• 239000003826 tablet Substances 0.000 description 12
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
• 239000000284 extract Substances 0.000 description 11
• 238000004128 high performance liquid chromatography Methods 0.000 description 11
• 238000010992 reflux Methods 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 208000004454 Hyperalgesia Diseases 0.000 description 10
• 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 10
• 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 10
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 239000010410 layer Substances 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 9
• 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 208000028017 Psychotic disease Diseases 0.000 description 9
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
• 235000019341 magnesium sulphate Nutrition 0.000 description 9
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
• 239000011347 resin Substances 0.000 description 9
• 229920005989 resin Polymers 0.000 description 9
• 229910052938 sodium sulfate Inorganic materials 0.000 description 9
• 235000011152 sodium sulphate Nutrition 0.000 description 9
• 210000004027 cell Anatomy 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000014759 maintenance of location Effects 0.000 description 8
• 229910052757 nitrogen Inorganic materials 0.000 description 8
• 239000012044 organic layer Substances 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 229910000104 sodium hydride Inorganic materials 0.000 description 8
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
• 239000007832 Na2SO4 Substances 0.000 description 7
• 230000001154 acute effect Effects 0.000 description 7
• 206010053552 allodynia Diseases 0.000 description 7
• 150000001450 anions Chemical class 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 125000002950 monocyclic group Chemical group 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 208000019901 Anxiety disease Diseases 0.000 description 6
• 206010012289 Dementia Diseases 0.000 description 6
• 208000023105 Huntington disease Diseases 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 208000016285 Movement disease Diseases 0.000 description 6
• 208000018737 Parkinson disease Diseases 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 6
• 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 125000001153 fluoro group Chemical group F* 0.000 description 6
• 239000001530 fumaric acid Substances 0.000 description 6
• AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 239000003176 neuroleptic agent Substances 0.000 description 6
• 230000000701 neuroleptic effect Effects 0.000 description 6
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 239000003643 water by type Substances 0.000 description 6
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 5
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 5
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 239000000935 antidepressant agent Substances 0.000 description 5
• 229940005513 antidepressants Drugs 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000000706 filtrate Substances 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 4
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• 208000020925 Bipolar disease Diseases 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• 206010012335 Dependence Diseases 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 125000003118 aryl group Chemical group 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
• 239000008120 corn starch Substances 0.000 description 4
• 229940099112 cornstarch Drugs 0.000 description 4
• VCJZTATVUDMNLU-UHFFFAOYSA-N dibromomethylbenzene Chemical compound BrC(Br)C1=CC=CC=C1 VCJZTATVUDMNLU-UHFFFAOYSA-N 0.000 description 4
• 238000001035 drying Methods 0.000 description 4
• 208000024732 dysthymic disease Diseases 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 208000024714 major depressive disease Diseases 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229920001467 poly(styrenesulfonates) Polymers 0.000 description 4
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 4
• APCBTRDHCDOPNY-ZETCQYMHSA-N tert-butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)C1 APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
• GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 3
• KTOJGSDLJNUAEP-UHFFFAOYSA-N (2,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1F KTOJGSDLJNUAEP-UHFFFAOYSA-N 0.000 description 3
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
• 238000005160 1H NMR spectroscopy Methods 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• 208000008811 Agoraphobia Diseases 0.000 description 3
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 3
• 208000000094 Chronic Pain Diseases 0.000 description 3
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 3
• 206010019233 Headaches Diseases 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 208000008930 Low Back Pain Diseases 0.000 description 3
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 229920002873 Polyethylenimine Polymers 0.000 description 3
• 208000004550 Postoperative Pain Diseases 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 239000002249 anxiolytic agent Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 239000003693 atypical antipsychotic agent Substances 0.000 description 3
• 229940127236 atypical antipsychotics Drugs 0.000 description 3
• 229940049706 benzodiazepine Drugs 0.000 description 3
• 150000001557 benzodiazepines Chemical class 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 235000017663 capsaicin Nutrition 0.000 description 3
• 229960002504 capsaicin Drugs 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 150000001924 cycloalkanes Chemical class 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 229960003529 diazepam Drugs 0.000 description 3
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000003818 flash chromatography Methods 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 229960002464 fluoxetine Drugs 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 210000000548 hind-foot Anatomy 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 229940009697 lyrica Drugs 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 230000002981 neuropathic effect Effects 0.000 description 3
• 208000015238 neurotic disease Diseases 0.000 description 3
• 229960002715 nicotine Drugs 0.000 description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 3
• 208000019906 panic disease Diseases 0.000 description 3
• 229960002296 paroxetine Drugs 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 229940044551 receptor antagonist Drugs 0.000 description 3
• 239000002464 receptor antagonist Substances 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• IYXWLECKEMUWSU-KRWDZBQOSA-N tert-butyl (3s)-3-[[2-(2,4-difluorophenyl)phenyl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=CC=CC=C1C1=CC=C(F)C=C1F IYXWLECKEMUWSU-KRWDZBQOSA-N 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
• LIWAGWJMSCJMOO-KRWDZBQOSA-N (3s)-3-[[2-(2,3-dimethylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1C LIWAGWJMSCJMOO-KRWDZBQOSA-N 0.000 description 2
• MBHOQWDDYILYON-AWEZNQCLSA-N (3s)-3-[[2-(2-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 MBHOQWDDYILYON-AWEZNQCLSA-N 0.000 description 2
• XXBOZIOSMKDDRY-HNNXBMFYSA-N (3s)-3-[[2-(2-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 XXBOZIOSMKDDRY-HNNXBMFYSA-N 0.000 description 2
• KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 description 2
• GUEQOLSQPOTTME-RQJHMYQMSA-N (3s,5r)-3-amino-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](N)CC(O)=O GUEQOLSQPOTTME-RQJHMYQMSA-N 0.000 description 2
• XKWDZEJCUWTBOM-BDAKNGLRSA-N (3s,5r)-3-amino-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](N)CC(O)=O XKWDZEJCUWTBOM-BDAKNGLRSA-N 0.000 description 2
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
• LZSYGJNFCREHMD-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1Br LZSYGJNFCREHMD-UHFFFAOYSA-N 0.000 description 2
• PSZFWIMCOWKKAG-UHFFFAOYSA-N 2-(bromomethyl)-3-(2,5-difluorophenyl)pyridine Chemical compound FC1=CC=C(F)C(C=2C(=NC=CC=2)CBr)=C1 PSZFWIMCOWKKAG-UHFFFAOYSA-N 0.000 description 2
• JXSBZOVCVUSLIO-NQMVMOMDSA-N 2-[(1r,5r,6s)-6-(aminomethyl)-6-bicyclo[3.2.0]heptanyl]acetic acid Chemical compound C1CC[C@H]2[C@@](CN)(CC(O)=O)C[C@H]21 JXSBZOVCVUSLIO-NQMVMOMDSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 2
• UBLPKSZFHUWFCB-UHFFFAOYSA-N 3-(bromomethyl)-2-(2,4-difluorophenyl)pyridine Chemical compound FC1=CC(F)=CC=C1C1=NC=CC=C1CBr UBLPKSZFHUWFCB-UHFFFAOYSA-N 0.000 description 2
• ZYJOGETZWYDXFE-HNNXBMFYSA-N 3-[2-[[(3s)-pyrrolidin-3-yl]methoxy]phenyl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C(=CC=CC=2)OC[C@@H]2CNCC2)=C1 ZYJOGETZWYDXFE-HNNXBMFYSA-N 0.000 description 2
• MOEZPHHJIZLEKX-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCCC1 MOEZPHHJIZLEKX-UHFFFAOYSA-N 0.000 description 2
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
• 206010001541 Akinesia Diseases 0.000 description 2
• IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• 208000006373 Bell palsy Diseases 0.000 description 2
• 239000004342 Benzoyl peroxide Substances 0.000 description 2
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
• 208000021465 Brief psychotic disease Diseases 0.000 description 2
• KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
• 206010058019 Cancer Pain Diseases 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 206010008748 Chorea Diseases 0.000 description 2
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
• 208000027691 Conduct disease Diseases 0.000 description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
• 206010012218 Delirium Diseases 0.000 description 2
• 208000024254 Delusional disease Diseases 0.000 description 2
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• 208000012661 Dyskinesia Diseases 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 208000026139 Memory disease Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• 102000010909 Monoamine Oxidase Human genes 0.000 description 2
• 108010062431 Monoamine oxidase Proteins 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 208000008238 Muscle Spasticity Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 2
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
• 208000027089 Parkinsonian disease Diseases 0.000 description 2
• 206010034010 Parkinsonism Diseases 0.000 description 2
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
• 208000004983 Phantom Limb Diseases 0.000 description 2
• 206010034912 Phobia Diseases 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 206010073211 Postural tremor Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 201000000552 Scott syndrome Diseases 0.000 description 2
• 206010039966 Senile dementia Diseases 0.000 description 2
• 208000019568 Shared Paranoid disease Diseases 0.000 description 2
• 206010041250 Social phobia Diseases 0.000 description 2
• 102100037346 Substance-P receptor Human genes 0.000 description 2
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
• 208000000323 Tourette Syndrome Diseases 0.000 description 2
• 208000016620 Tourette disease Diseases 0.000 description 2
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• WNYOFKAAWGYNNG-UHFFFAOYSA-N [2-(2,4-difluorophenyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=CN=C1C1=CC=C(F)C=C1F WNYOFKAAWGYNNG-UHFFFAOYSA-N 0.000 description 2
• NCFUQLMCNPXNNW-UHFFFAOYSA-N [3-(2,5-difluorophenyl)pyridin-2-yl]methanol Chemical compound OCC1=NC=CC=C1C1=CC(F)=CC=C1F NCFUQLMCNPXNNW-UHFFFAOYSA-N 0.000 description 2
• DMXFNZYCPGEKIG-UHFFFAOYSA-N [3-(2,5-difluorophenyl)pyridin-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=NC=CC=C1C1=CC(F)=CC=C1F DMXFNZYCPGEKIG-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 208000005298 acute pain Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
• 230000001430 anti-depressive effect Effects 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• 235000019400 benzoyl peroxide Nutrition 0.000 description 2
• 208000028683 bipolar I disease Diseases 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000003461 brachial plexus Anatomy 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 210000003710 cerebral cortex Anatomy 0.000 description 2
• 206010008129 cerebral palsy Diseases 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 229960001653 citalopram Drugs 0.000 description 2
• 229960004606 clomipramine Drugs 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 2
• 229960003572 cyclobenzaprine Drugs 0.000 description 2
• 208000026725 cyclothymic disease Diseases 0.000 description 2
• 229960003914 desipramine Drugs 0.000 description 2
• LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• 229960002866 duloxetine Drugs 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• NRGVIUYXTTVMHP-UHFFFAOYSA-N ethyl 3-(2,5-difluorophenyl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=NC=CC=C1C1=CC(F)=CC=C1F NRGVIUYXTTVMHP-UHFFFAOYSA-N 0.000 description 2
• XNBWTVJGOWNRFG-UHFFFAOYSA-N ethyl 3-(trifluoromethylsulfonyloxy)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=NC=CC=C1OS(=O)(=O)C(F)(F)F XNBWTVJGOWNRFG-UHFFFAOYSA-N 0.000 description 2
• NNYREQBXDUEBDD-UHFFFAOYSA-N ethyl 3-hydroxypyridine-2-carboxylate Chemical compound CCOC(=O)C1=NC=CC=C1O NNYREQBXDUEBDD-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 229940050410 gluconate Drugs 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 150000004678 hydrides Chemical class 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• JXEHXYFSIOYTAH-SFYZADRCSA-N imagabalin Chemical compound CCC[C@@H](C)C[C@H](N)CC(O)=O JXEHXYFSIOYTAH-SFYZADRCSA-N 0.000 description 2
• 229960004801 imipramine Drugs 0.000 description 2
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• BSWLTXKQXURJIY-UHFFFAOYSA-N methyl 2-(2,4-difluorophenyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1C1=CC=C(F)C=C1F BSWLTXKQXURJIY-UHFFFAOYSA-N 0.000 description 2
• MYGAJZBZLONIBZ-UHFFFAOYSA-N methyl 2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Cl MYGAJZBZLONIBZ-UHFFFAOYSA-N 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 150000004702 methyl esters Chemical class 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 229960000600 milnacipran Drugs 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 2
• 229940072228 neurontin Drugs 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 229960001158 nortriptyline Drugs 0.000 description 2
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 208000002851 paranoid schizophrenia Diseases 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 208000030062 persistent idiopathic facial pain Diseases 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000002798 polar solvent Substances 0.000 description 2
• 208000028173 post-traumatic stress disease Diseases 0.000 description 2
• 239000011698 potassium fluoride Substances 0.000 description 2
• 235000003270 potassium fluoride Nutrition 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 201000002241 progressive bulbar palsy Diseases 0.000 description 2
• 230000001107 psychogenic effect Effects 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 239000002287 radioligand Substances 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
• 230000008653 root damage Effects 0.000 description 2
• 150000003335 secondary amines Chemical class 0.000 description 2
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
• GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
• 229960002073 sertraline Drugs 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
• 208000018198 spasticity Diseases 0.000 description 2
• 201000001716 specific phobia Diseases 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 125000005415 substituted alkoxy group Chemical group 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• GPYNJSCCAXZWRH-KRWDZBQOSA-N tert-butyl (3s)-3-[[2-cyano-6-(2,5-difluorophenyl)phenyl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=C(C#N)C=CC=C1C1=CC(F)=CC=C1F GPYNJSCCAXZWRH-KRWDZBQOSA-N 0.000 description 2
• CMIBWIAICVBURI-ZETCQYMHSA-N tert-butyl (3s)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](N)C1 CMIBWIAICVBURI-ZETCQYMHSA-N 0.000 description 2
• WXDABEPNSCXCRD-UHFFFAOYSA-N tert-butyl 3-[(2-phenylphenyl)methylamino]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1NCC1=CC=CC=C1C1=CC=CC=C1 WXDABEPNSCXCRD-UHFFFAOYSA-N 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 229960004394 topiramate Drugs 0.000 description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 description 2
• 229960004688 venlafaxine Drugs 0.000 description 2
• 239000008215 water for injection Substances 0.000 description 2
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
• CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• UQQORXKOSAMAGS-ZOWNYOTGSA-N (3S)-3-[[2-(2,4-difluorophenyl)-3-fluorophenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.Fc1ccc(c(F)c1)-c1c(F)cccc1CO[C@H]1CCNC1 UQQORXKOSAMAGS-ZOWNYOTGSA-N 0.000 description 1
• AZXZUGCVOCVEIW-RSAXXLAASA-N (3S)-3-[[2-(2-methylsulfanylphenyl)phenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.CSc1ccccc1-c1ccccc1CO[C@H]1CCNC1 AZXZUGCVOCVEIW-RSAXXLAASA-N 0.000 description 1
• VKVUREIYGPZYFE-NTISSMGPSA-N (3S)-3-[[2-(3,5-difluorophenyl)phenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.Fc1cc(F)cc(c1)-c1ccccc1CO[C@H]1CCNC1 VKVUREIYGPZYFE-NTISSMGPSA-N 0.000 description 1
• JVYPPISABRHSQL-NTISSMGPSA-N (3S)-3-[[2-(4-fluoro-2-methylphenyl)phenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.Cc1cc(F)ccc1-c1ccccc1CO[C@H]1CCNC1 JVYPPISABRHSQL-NTISSMGPSA-N 0.000 description 1
• CGPBLPZXIBGOET-NTISSMGPSA-N (3S)-3-[[2-[3-(trifluoromethyl)phenyl]phenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.FC(F)(F)c1cccc(c1)-c1ccccc1CO[C@H]1CCNC1 CGPBLPZXIBGOET-NTISSMGPSA-N 0.000 description 1
• OSWHOPGSYNEQFC-ZOWNYOTGSA-N (3S)-3-[[3-fluoro-2-(2-fluorophenyl)phenyl]methoxy]pyrrolidine hydrochloride Chemical compound Cl.Fc1ccccc1-c1c(F)cccc1CO[C@H]1CCNC1 OSWHOPGSYNEQFC-ZOWNYOTGSA-N 0.000 description 1
• IMYUZNXLNQZFHX-PKLMIRHRSA-N (3r)-3-[(2-phenylphenyl)methoxy]pyrrolidine;hydrochloride Chemical compound Cl.C=1C=CC=C(C=2C=CC=CC=2)C=1CO[C@@H]1CCNC1 IMYUZNXLNQZFHX-PKLMIRHRSA-N 0.000 description 1
• HRRMCOCCVAGSNJ-SFHVURJKSA-N (3s)-3-[(2-naphthalen-1-ylphenyl)methoxy]pyrrolidine Chemical compound C=1C=CC=C(C=2C3=CC=CC=C3C=CC=2)C=1CO[C@H]1CCNC1 HRRMCOCCVAGSNJ-SFHVURJKSA-N 0.000 description 1
• IMYUZNXLNQZFHX-NTISSMGPSA-N (3s)-3-[(2-phenylphenyl)methoxy]pyrrolidine;hydrochloride Chemical compound Cl.C=1C=CC=C(C=2C=CC=CC=2)C=1CO[C@H]1CCNC1 IMYUZNXLNQZFHX-NTISSMGPSA-N 0.000 description 1
• BFPFBXPZBYYZME-INIZCTEOSA-N (3s)-3-[(5-fluoro-2-phenylphenyl)methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=CC=CC=2)C=1CO[C@H]1CCNC1 BFPFBXPZBYYZME-INIZCTEOSA-N 0.000 description 1
• LZDCYXCPMAHCLC-KRWDZBQOSA-N (3s)-3-[[2-(2,3-dihydro-1-benzofuran-5-yl)phenyl]methoxy]pyrrolidine Chemical compound C=1C=CC=C(C=2C=C3CCOC3=CC=2)C=1CO[C@H]1CCNC1 LZDCYXCPMAHCLC-KRWDZBQOSA-N 0.000 description 1
• XTFPLFPPNYEFFG-KRWDZBQOSA-N (3s)-3-[[2-(2,3-dimethylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound CC1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1C XTFPLFPPNYEFFG-KRWDZBQOSA-N 0.000 description 1
• VJIVCMOCGISDBU-INIZCTEOSA-N (3s)-3-[[2-(2,4-dimethoxyphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 VJIVCMOCGISDBU-INIZCTEOSA-N 0.000 description 1
• YPKPIOUHPBKJTK-INIZCTEOSA-N (3s)-3-[[2-(2,4-dimethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 YPKPIOUHPBKJTK-INIZCTEOSA-N 0.000 description 1
• ZYCGURXCRBWMND-AWEZNQCLSA-N (3s)-3-[[2-(2,5-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=C(F)C(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 ZYCGURXCRBWMND-AWEZNQCLSA-N 0.000 description 1
• QHBWEKJVRBHNGC-KRWDZBQOSA-N (3s)-3-[[2-(2,5-dimethylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound CC1=CC=C(C)C(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 QHBWEKJVRBHNGC-KRWDZBQOSA-N 0.000 description 1
• BVIWDQWWOWSJSM-KRWDZBQOSA-N (3s)-3-[[2-(2,5-dimethylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC=C(C)C(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 BVIWDQWWOWSJSM-KRWDZBQOSA-N 0.000 description 1
• CCLMVGNHTOOXNM-AWEZNQCLSA-N (3s)-3-[[2-(2-chloro-5-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=C(Cl)C(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 CCLMVGNHTOOXNM-AWEZNQCLSA-N 0.000 description 1
• YKEZRZYSFDEPEG-AWEZNQCLSA-N (3s)-3-[[2-(2-chlorophenyl)phenyl]methoxy]pyrrolidine Chemical compound ClC1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 YKEZRZYSFDEPEG-AWEZNQCLSA-N 0.000 description 1
• ZJEKYECSABMXDS-KRWDZBQOSA-N (3s)-3-[[2-(2-ethylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound CCC1=CC=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 ZJEKYECSABMXDS-KRWDZBQOSA-N 0.000 description 1
• UZXKENNIBPENDG-INIZCTEOSA-N (3s)-3-[[2-(2-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 UZXKENNIBPENDG-INIZCTEOSA-N 0.000 description 1
• QNLGVPIWROOIKY-NRFANRHFSA-N (3s)-3-[[2-(2-phenylmethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C=1C=CC=C(C=2C(=CC=CC=2)OCC=2C=CC=CC=2)C=1CO[C@H]1CCNC1 QNLGVPIWROOIKY-NRFANRHFSA-N 0.000 description 1
• CBFBAUCNAWVNLN-INIZCTEOSA-N (3s)-3-[[2-(3,4,5-trimethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 CBFBAUCNAWVNLN-INIZCTEOSA-N 0.000 description 1
• BBCZIZZMBRUKNM-AWEZNQCLSA-N (3s)-3-[[2-(3,4-dichlorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 BBCZIZZMBRUKNM-AWEZNQCLSA-N 0.000 description 1
• LYZAKCUAFAGBHK-KRWDZBQOSA-N (3s)-3-[[2-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)phenyl]methoxy]pyrrolidine Chemical compound C=1C=CC=C(C=2C=C3OCCCOC3=CC=2)C=1CO[C@H]1CCNC1 LYZAKCUAFAGBHK-KRWDZBQOSA-N 0.000 description 1
• WTWMBZKRQGNASI-INIZCTEOSA-N (3s)-3-[[2-(3,4-dimethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 WTWMBZKRQGNASI-INIZCTEOSA-N 0.000 description 1
• RHKMDWOBNJGCDZ-SFHVURJKSA-N (3s)-3-[[2-(3,4-dimethylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C1=C(C)C(C)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 RHKMDWOBNJGCDZ-SFHVURJKSA-N 0.000 description 1
• GLWUVRKILMQILD-SFHVURJKSA-N (3s)-3-[[2-(3,4-dimethylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(C)C(C)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 GLWUVRKILMQILD-SFHVURJKSA-N 0.000 description 1
• YNXQUFUORRHJPT-SFHVURJKSA-N (3s)-3-[[2-(3,5-dimethylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC(C)=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 YNXQUFUORRHJPT-SFHVURJKSA-N 0.000 description 1
• DEVCUPJFLGSFRA-AWEZNQCLSA-N (3s)-3-[[2-(3-chloro-4-fluorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=C(Cl)C(F)=CC=2)C=1CO[C@H]1CCNC1 DEVCUPJFLGSFRA-AWEZNQCLSA-N 0.000 description 1
• ZFOJHUZEVLPDCH-AWEZNQCLSA-N (3s)-3-[[2-(3-chloro-4-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(Cl)C(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 ZFOJHUZEVLPDCH-AWEZNQCLSA-N 0.000 description 1
• KBCPMDGEWHMBOR-INIZCTEOSA-N (3s)-3-[[2-(3-chlorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=C(Cl)C=CC=2)C=1CO[C@H]1CCNC1 KBCPMDGEWHMBOR-INIZCTEOSA-N 0.000 description 1
• CLZMXWHONSVRFS-INIZCTEOSA-N (3s)-3-[[2-(3-chlorophenyl)phenyl]methoxy]pyrrolidine Chemical compound ClC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 CLZMXWHONSVRFS-INIZCTEOSA-N 0.000 description 1
• PDAWZJGFRQQKDC-SFHVURJKSA-N (3s)-3-[[2-(3-ethoxyphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound CCOC1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 PDAWZJGFRQQKDC-SFHVURJKSA-N 0.000 description 1
• CJFAEVBFQNHUGK-SFHVURJKSA-N (3s)-3-[[2-(3-ethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound CCOC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 CJFAEVBFQNHUGK-SFHVURJKSA-N 0.000 description 1
• LTIKFTKEALGPOO-HNNXBMFYSA-N (3s)-3-[[2-(3-fluoro-4-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 LTIKFTKEALGPOO-HNNXBMFYSA-N 0.000 description 1
• KGNNBCLWLMYUCU-INIZCTEOSA-N (3s)-3-[[2-(3-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 KGNNBCLWLMYUCU-INIZCTEOSA-N 0.000 description 1
• XJVBKGMCAKJZTO-KRWDZBQOSA-N (3s)-3-[[2-(3-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 XJVBKGMCAKJZTO-KRWDZBQOSA-N 0.000 description 1
• NXFLMLZIKJGNKM-KRWDZBQOSA-N (3s)-3-[[2-(3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 NXFLMLZIKJGNKM-KRWDZBQOSA-N 0.000 description 1
• MSDATJPRUPUYQC-INIZCTEOSA-N (3s)-3-[[2-(3-methylsulfanylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CSC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 MSDATJPRUPUYQC-INIZCTEOSA-N 0.000 description 1
• UHXQSFNWQRZNNP-INIZCTEOSA-N (3s)-3-[[2-(4-chlorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=CC(Cl)=CC=2)C=1CO[C@H]1CCNC1 UHXQSFNWQRZNNP-INIZCTEOSA-N 0.000 description 1
• PVYFVGXETGIVBM-INIZCTEOSA-N (3s)-3-[[2-(4-chlorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 PVYFVGXETGIVBM-INIZCTEOSA-N 0.000 description 1
• UJJWTXRGCSWEQW-SFHVURJKSA-N (3s)-3-[[2-(4-ethoxyphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C1=CC(OCC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 UJJWTXRGCSWEQW-SFHVURJKSA-N 0.000 description 1
• WRTLZUYUHSPRMJ-SFHVURJKSA-N (3s)-3-[[2-(4-ethoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(OCC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 WRTLZUYUHSPRMJ-SFHVURJKSA-N 0.000 description 1
• LFGZKNFEQJXXEZ-SFHVURJKSA-N (3s)-3-[[2-(4-ethylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C1=CC(CC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 LFGZKNFEQJXXEZ-SFHVURJKSA-N 0.000 description 1
• CFBPNCZETLOZLP-KRWDZBQOSA-N (3s)-3-[[2-(4-ethylsulfonylphenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 CFBPNCZETLOZLP-KRWDZBQOSA-N 0.000 description 1
• PEMNASDUBJEPFQ-KRWDZBQOSA-N (3s)-3-[[2-(4-ethylsulfonylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 PEMNASDUBJEPFQ-KRWDZBQOSA-N 0.000 description 1
• LBPJPJJFRXMHML-INIZCTEOSA-N (3s)-3-[[2-(4-fluoro-3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(F)C(C)=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 LBPJPJJFRXMHML-INIZCTEOSA-N 0.000 description 1
• ODWPZJIBDWVELQ-KRWDZBQOSA-N (3s)-3-[[2-(4-methoxy-3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(C)C(OC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 ODWPZJIBDWVELQ-KRWDZBQOSA-N 0.000 description 1
• BINBVCJSCJZNQU-KRWDZBQOSA-N (3s)-3-[[2-(4-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 BINBVCJSCJZNQU-KRWDZBQOSA-N 0.000 description 1
• WOJVAZYBMAAKSN-AWEZNQCLSA-N (3s)-3-[[2-(5-chloro-2-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=C(Cl)C=C1C1=CC=CC=C1CO[C@@H]1CNCC1 WOJVAZYBMAAKSN-AWEZNQCLSA-N 0.000 description 1
• VZOLMQDSRSTPMM-HNNXBMFYSA-N (3s)-3-[[2-(5-chloro-2-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=C(Cl)C=C1C1=CC=CC=C1CO[C@@H]1CNCC1 VZOLMQDSRSTPMM-HNNXBMFYSA-N 0.000 description 1
• UJXSRRZTKLOCFR-AWEZNQCLSA-N (3s)-3-[[2-[2-(trifluoromethoxy)phenyl]phenyl]methoxy]pyrrolidine Chemical compound FC(F)(F)OC1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 UJXSRRZTKLOCFR-AWEZNQCLSA-N 0.000 description 1
• RQMXACJRNYRGGL-INIZCTEOSA-N (3s)-3-[[2-[3-(trifluoromethoxy)phenyl]phenyl]methoxy]pyrrolidine Chemical compound FC(F)(F)OC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 RQMXACJRNYRGGL-INIZCTEOSA-N 0.000 description 1
• VLTMWEZGIPUSQN-INIZCTEOSA-N (3s)-3-[[2-[4-(trifluoromethoxy)phenyl]phenyl]methoxy]pyrrolidine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 VLTMWEZGIPUSQN-INIZCTEOSA-N 0.000 description 1
• NXHHPXQAIYTFEK-INIZCTEOSA-N (3s)-3-[[2-[4-(trifluoromethyl)phenyl]phenyl]methoxy]pyrrolidine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 NXHHPXQAIYTFEK-INIZCTEOSA-N 0.000 description 1
• ISSIRPRRZOZCGH-HNNXBMFYSA-N (3s)-3-[[5-fluoro-2-(2-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 ISSIRPRRZOZCGH-HNNXBMFYSA-N 0.000 description 1
• IOMIDHMCDQKKGA-HNNXBMFYSA-N (3s)-3-[[5-fluoro-2-(3-fluoro-4-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 IOMIDHMCDQKKGA-HNNXBMFYSA-N 0.000 description 1
• AVOANIWPRYSVSX-INIZCTEOSA-N (3s)-3-[[5-fluoro-2-(3-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound FC1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 AVOANIWPRYSVSX-INIZCTEOSA-N 0.000 description 1
• ZXNLJLHHAMXCBJ-KRWDZBQOSA-N (3s)-3-[[5-fluoro-2-(3-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 ZXNLJLHHAMXCBJ-KRWDZBQOSA-N 0.000 description 1
• KPQUAAJIIOVXHJ-KRWDZBQOSA-N (3s)-3-[[5-fluoro-2-(3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound CC1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 KPQUAAJIIOVXHJ-KRWDZBQOSA-N 0.000 description 1
• DLCUJERBNAMQLK-INIZCTEOSA-N (3s)-3-[[5-fluoro-2-(4-fluoro-3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(F)C(C)=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 DLCUJERBNAMQLK-INIZCTEOSA-N 0.000 description 1
• GUCHSOMBBVRBIA-INIZCTEOSA-N (3s)-3-[[5-fluoro-2-(4-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(F)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 GUCHSOMBBVRBIA-INIZCTEOSA-N 0.000 description 1
• NEMWRFDKCFQVTK-KRWDZBQOSA-N (3s)-3-[[5-fluoro-2-(4-methoxy-3-methylphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=C(C)C(OC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 NEMWRFDKCFQVTK-KRWDZBQOSA-N 0.000 description 1
• FKDYMZQYRBITLK-KRWDZBQOSA-N (3s)-3-[[5-fluoro-2-(4-methoxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 FKDYMZQYRBITLK-KRWDZBQOSA-N 0.000 description 1
• ARAFADXIPYTQJR-IBGZPJMESA-N (3s)-3-[[5-fluoro-2-(4-propan-2-yloxyphenyl)phenyl]methoxy]pyrrolidine Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 ARAFADXIPYTQJR-IBGZPJMESA-N 0.000 description 1
• QFCQQGVZHDRXFG-INIZCTEOSA-N (3s)-3-[[5-fluoro-2-[3-(trifluoromethoxy)phenyl]phenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=C(OC(F)(F)F)C=CC=2)C=1CO[C@H]1CCNC1 QFCQQGVZHDRXFG-INIZCTEOSA-N 0.000 description 1
• OIAXDKFZTSMMIU-INIZCTEOSA-N (3s)-3-[[5-fluoro-2-[4-(trifluoromethoxy)phenyl]phenyl]methoxy]pyrrolidine Chemical compound C=1C(F)=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)C=1CO[C@H]1CCNC1 OIAXDKFZTSMMIU-INIZCTEOSA-N 0.000 description 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
• KMJGDROMSLRFJA-WRYMNLRPSA-N (E)-but-2-enedioic acid (3S)-3-[[2-(2,3-difluorophenyl)-4,5-difluorophenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.Fc1c(F)cccc1-c1cc(F)c(F)cc1CO[C@H]1CCNC1 KMJGDROMSLRFJA-WRYMNLRPSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
• IXZHBXVDDUPSDB-CSCOWPIISA-N (e)-but-2-enedioic acid;(3r)-3-[[2-(2,3-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=CC(C=2C(=CC=CC=2)CO[C@H]2CNCC2)=C1F IXZHBXVDDUPSDB-CSCOWPIISA-N 0.000 description 1
• VXVRZMHMSSJNJK-WZGZYPNHSA-N (e)-but-2-enedioic acid;(3r)-3-[[2-(2,4-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C1=CC=CC=C1CO[C@H]1CNCC1 VXVRZMHMSSJNJK-WZGZYPNHSA-N 0.000 description 1
• FMTSRENZIKCDPC-WZGZYPNHSA-N (e)-but-2-enedioic acid;(3r)-3-[[2-(2-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=CC=C1C1=CC=CC=C1CO[C@H]1CNCC1 FMTSRENZIKCDPC-WZGZYPNHSA-N 0.000 description 1
• SSSBFKBTGOUFOK-WZGZYPNHSA-N (e)-but-2-enedioic acid;(3r)-3-[[2-(3,4-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(F)=CC=C1C1=CC=CC=C1CO[C@H]1CNCC1 SSSBFKBTGOUFOK-WZGZYPNHSA-N 0.000 description 1
• SOLHXZUSTRRSEO-KZHAMYRLSA-N (e)-but-2-enedioic acid;(3s)-3-[[2-(2,4-difluorophenyl)-5-fluorophenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 SOLHXZUSTRRSEO-KZHAMYRLSA-N 0.000 description 1
• VXVRZMHMSSJNJK-KZHAMYRLSA-N (e)-but-2-enedioic acid;(3s)-3-[[2-(2,4-difluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 VXVRZMHMSSJNJK-KZHAMYRLSA-N 0.000 description 1
• XVSLZZZRBGQBIQ-KZHAMYRLSA-N (e)-but-2-enedioic acid;(3s)-3-[[5-fluoro-2-(2-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.C=1C(F)=CC=C(C=2C(=CC=CC=2)F)C=1CO[C@H]1CCNC1 XVSLZZZRBGQBIQ-KZHAMYRLSA-N 0.000 description 1
• CWZVBZYCOMZNGZ-GCQRLXCUSA-N (e)-but-2-enedioic acid;(3s)-n-ethyl-n-[(2-phenylphenyl)methyl]pyrrolidin-3-amine Chemical compound OC(=O)\C=C\C(O)=O.CCN([C@@H]1CNCC1)CC1=CC=CC=C1C1=CC=CC=C1 CWZVBZYCOMZNGZ-GCQRLXCUSA-N 0.000 description 1
• JFZDAEJGYMOILU-GYDOPSIJSA-N (e)-but-2-enedioic acid;2-(2,3-difluorophenyl)-3-[[(3s)-pyrrolidin-3-yl]oxymethyl]pyridine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=CC(C=2C(=CC=CN=2)CO[C@@H]2CNCC2)=C1F JFZDAEJGYMOILU-GYDOPSIJSA-N 0.000 description 1
• RMPDRUGVRYGPLP-QDSMGTAFSA-N (e)-but-2-enedioic acid;2-(2,4-difluorophenyl)-3-[[(3s)-pyrrolidin-3-yl]oxymethyl]pyridine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C1=NC=CC=C1CO[C@@H]1CNCC1 RMPDRUGVRYGPLP-QDSMGTAFSA-N 0.000 description 1
• JDKRNYUZKKPKEN-QDSMGTAFSA-N (e)-but-2-enedioic acid;2-(3,4-difluorophenyl)-3-[[(3s)-pyrrolidin-3-yl]oxymethyl]pyridine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(F)=CC=C1C1=NC=CC=C1CO[C@@H]1CNCC1 JDKRNYUZKKPKEN-QDSMGTAFSA-N 0.000 description 1
• OHYXWTGCLDNWEY-QDSMGTAFSA-N (e)-but-2-enedioic acid;3-(2,3-difluorophenyl)-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]benzonitrile Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=CC(C=2C(=C(C#N)C=CC=2)CO[C@@H]2CNCC2)=C1F OHYXWTGCLDNWEY-QDSMGTAFSA-N 0.000 description 1
• XCGHXQWEKQQINJ-KZHAMYRLSA-N (e)-but-2-enedioic acid;3-(2,4-difluorophenyl)-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]benzonitrile Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC(F)=CC=C1C1=CC=CC(C#N)=C1CO[C@@H]1CNCC1 XCGHXQWEKQQINJ-KZHAMYRLSA-N 0.000 description 1
• TVFQOQZECQNKLH-KZHAMYRLSA-N (e)-but-2-enedioic acid;3-(2,5-difluorophenyl)-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]benzonitrile Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C(F)C(C=2C(=C(C#N)C=CC=2)CO[C@@H]2CNCC2)=C1 TVFQOQZECQNKLH-KZHAMYRLSA-N 0.000 description 1
• KHCBSMSBMWSYTJ-ZSJYYTRTSA-N (z)-but-2-enedioic acid;(3s)-3-[[2-(4-fluorophenyl)phenyl]methoxy]pyrrolidine Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 KHCBSMSBMWSYTJ-ZSJYYTRTSA-N 0.000 description 1
• TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
• WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
• WAMIHUFHVGNDMF-IBGZPJMESA-N 1-[3-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]phenyl]pyrazole Chemical compound C=1C(F)=CC=C(C=2C=C(C=CC=2)N2N=CC=C2)C=1CO[C@H]1CCNC1 WAMIHUFHVGNDMF-IBGZPJMESA-N 0.000 description 1
• WRDTZAZLCRNNAF-SFHVURJKSA-N 1-[4-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 WRDTZAZLCRNNAF-SFHVURJKSA-N 0.000 description 1
• CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
• ZZBRTAXRIKBTMY-UHFFFAOYSA-N 2-(bromomethyl)-3-chlorobenzonitrile Chemical compound ClC1=CC=CC(C#N)=C1CBr ZZBRTAXRIKBTMY-UHFFFAOYSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• VRHJBWUIWQOFLF-WLHGVMLRSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 VRHJBWUIWQOFLF-WLHGVMLRSA-N 0.000 description 1
• HEPWMLYERDGRQD-AWEZNQCLSA-N 2-[2-[[(3s)-pyrrolidin-3-yl]methoxy]phenyl]benzonitrile Chemical compound N#CC1=CC=CC=C1C1=CC=CC=C1OC[C@@H]1CNCC1 HEPWMLYERDGRQD-AWEZNQCLSA-N 0.000 description 1
• CUGFSKNLTROCHN-AWEZNQCLSA-N 2-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]phenol Chemical compound OC1=CC=CC=C1C1=CC=C(F)C=C1CO[C@@H]1CNCC1 CUGFSKNLTROCHN-AWEZNQCLSA-N 0.000 description 1
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
• MOEXFUIEXVMWEP-ZDUSSCGKSA-N 2-chloro-3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]pyridine Chemical compound ClC1=NC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 MOEXFUIEXVMWEP-ZDUSSCGKSA-N 0.000 description 1
• KKZUMAMOMRDVKA-UHFFFAOYSA-N 2-chloropropane Chemical group [CH2]C(C)Cl KKZUMAMOMRDVKA-UHFFFAOYSA-N 0.000 description 1
• XUBQBFFVFOZTNI-HNNXBMFYSA-N 2-ethoxy-3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]pyridine Chemical compound CCOC1=NC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 XUBQBFFVFOZTNI-HNNXBMFYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• DNHAZMSCDWSPOF-FQEVSTJZSA-N 2-methoxy-N,N-di(propan-2-yl)-6-[2-[[(3S)-pyrrolidin-3-yl]oxymethyl]phenyl]benzamide Chemical compound COc1cccc(-c2ccccc2CO[C@H]2CCNC2)c1C(=O)N(C(C)C)C(C)C DNHAZMSCDWSPOF-FQEVSTJZSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LCRCBXLHWTVPEQ-UHFFFAOYSA-N 2-phenylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1 LCRCBXLHWTVPEQ-UHFFFAOYSA-N 0.000 description 1
• DGHFLLHZXUOPHB-INIZCTEOSA-N 2-propan-2-yloxy-3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]pyridine Chemical compound CC(C)OC1=NC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 DGHFLLHZXUOPHB-INIZCTEOSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• AJYJUXQUFAQNLR-NRFANRHFSA-N 3,5-dimethyl-1-[3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]phenyl]pyrazole Chemical compound N1=C(C)C=C(C)N1C1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 AJYJUXQUFAQNLR-NRFANRHFSA-N 0.000 description 1
• UKPFXTOZQZSZGR-LBPRGKRZSA-N 3-(2,5-difluorophenyl)-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]pyridine Chemical compound FC1=CC=C(F)C(C=2C(=NC=CC=2)CO[C@@H]2CNCC2)=C1 UKPFXTOZQZSZGR-LBPRGKRZSA-N 0.000 description 1
• YTOXDDWXLMZYRU-RSAXXLAASA-N 3-[2-[[(3S)-pyrrolidin-3-yl]oxymethyl]phenyl]pyridine hydrochloride Chemical compound Cl.C(O[C@H]1CCNC1)c1ccccc1-c1cccnc1 YTOXDDWXLMZYRU-RSAXXLAASA-N 0.000 description 1
• UHMQHYLWBNVRRO-ZDUSSCGKSA-N 3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 UHMQHYLWBNVRRO-ZDUSSCGKSA-N 0.000 description 1
• BETIANLMODQOLF-INIZCTEOSA-N 3-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2C(=CC(F)=CC=2)CO[C@@H]2CNCC2)=C1 BETIANLMODQOLF-INIZCTEOSA-N 0.000 description 1
• PWHVTTOWGNBLNR-KRWDZBQOSA-N 3-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]benzonitrile Chemical compound C=1C(F)=CC=C(C=2C=C(C=CC=2)C#N)C=1CO[C@H]1CCNC1 PWHVTTOWGNBLNR-KRWDZBQOSA-N 0.000 description 1
• FKFZTNLSUJCIMG-UHFFFAOYSA-N 3-chloro-2-methylbenzonitrile Chemical compound CC1=C(Cl)C=CC=C1C#N FKFZTNLSUJCIMG-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• YBHUSJOAWKUBHY-HNNXBMFYSA-N 4-[2-[[(3s)-pyrrolidin-3-yl]methoxy]phenyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=CC=CC=C1OC[C@@H]1CNCC1 YBHUSJOAWKUBHY-HNNXBMFYSA-N 0.000 description 1
• GUBNPCCIHCSLFK-KRWDZBQOSA-N 4-[4-fluoro-2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]benzonitrile Chemical compound C=1C(F)=CC=C(C=2C=CC(=CC=2)C#N)C=1CO[C@H]1CCNC1 GUBNPCCIHCSLFK-KRWDZBQOSA-N 0.000 description 1
• SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
• IZUAVPXNEIJBBZ-UHFFFAOYSA-N 5-[2-[1-(1,2-benzothiazol-3-yl)piperazin-2-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;hydrate;hydrochloride Chemical compound O.Cl.C1=CC=C2C(N3CCNCC3CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 IZUAVPXNEIJBBZ-UHFFFAOYSA-N 0.000 description 1
• UWTRBFMJOWDOEF-INIZCTEOSA-N 5-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=CC=C(C=2C=C3C=CNC3=NC=2)C=1CO[C@H]1CCNC1 UWTRBFMJOWDOEF-INIZCTEOSA-N 0.000 description 1
• MVSUGDXPTRMCAX-INIZCTEOSA-N 5-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]quinoline Chemical compound C=1C=CC=C(C=2C3=CC=CN=C3C=CC=2)C=1CO[C@H]1CCNC1 MVSUGDXPTRMCAX-INIZCTEOSA-N 0.000 description 1
• 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
• 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
• XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• CGSAGZMUIPQLSE-DMYPFFKMSA-N C(C=CC(=O)O)(=O)O.FC=1C=CC=C(C1)C=1C(CC=CC1)(OC)CO[C@@H]1CNCC1 Chemical compound C(C=CC(=O)O)(=O)O.FC=1C=CC=C(C1)C=1C(CC=CC1)(OC)CO[C@@H]1CNCC1 CGSAGZMUIPQLSE-DMYPFFKMSA-N 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• WURDWNAWYCZAER-RSAXXLAASA-N Cl.C(O[C@H]1CCNC1)c1ccccc1-c1ccncc1 Chemical compound Cl.C(O[C@H]1CCNC1)c1ccccc1-c1ccncc1 WURDWNAWYCZAER-RSAXXLAASA-N 0.000 description 1
• QAQNWMHWZAMPTK-YDALLXLXSA-N Cl.Fc1cccc(c1F)-c1c(F)cccc1CO[C@H]1CCNC1 Chemical compound Cl.Fc1cccc(c1F)-c1c(F)cccc1CO[C@H]1CCNC1 QAQNWMHWZAMPTK-YDALLXLXSA-N 0.000 description 1
• 208000006561 Cluster Headache Diseases 0.000 description 1
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
• 206010013935 Dysmenorrhoea Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 206010016059 Facial pain Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
• WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010065390 Inflammatory pain Diseases 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• 208000007914 Labor Pain Diseases 0.000 description 1
• 208000035945 Labour pain Diseases 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000006670 Multiple fractures Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
• 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
• RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• MWHUWSHHLRRNNK-WRYMNLRPSA-N OC(=O)\C=C\C(O)=O.Fc1c(F)cccc1-c1cccc(F)c1CO[C@H]1CCNC1 Chemical compound OC(=O)\C=C\C(O)=O.Fc1c(F)cccc1-c1cccc(F)c1CO[C@H]1CCNC1 MWHUWSHHLRRNNK-WRYMNLRPSA-N 0.000 description 1
• SMBCKVPGKJRVNB-GYDOPSIJSA-N OC(=O)\C=C\C(O)=O.O([C@@H]1CNCC1)Cc1c(F)cccc1-c1c(F)cccc1 Chemical compound OC(=O)\C=C\C(O)=O.O([C@@H]1CNCC1)Cc1c(F)cccc1-c1c(F)cccc1 SMBCKVPGKJRVNB-GYDOPSIJSA-N 0.000 description 1
• CKCAMOCHWWOCJO-YAKGRJRBSA-N OC(=O)\C=C\C(O)=O.c1nc(OC)ccc1-c1ccccc1CO[C@H]1CCNC1 Chemical compound OC(=O)\C=C\C(O)=O.c1nc(OC)ccc1-c1ccccc1CO[C@H]1CCNC1 CKCAMOCHWWOCJO-YAKGRJRBSA-N 0.000 description 1
• 206010068106 Occipital neuralgia Diseases 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000012202 Pervasive developmental disease Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 201000009916 Postpartum depression Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 206010037213 Psychomotor retardation Diseases 0.000 description 1
• 208000027465 Psychotic Affective disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010049002 Scar pain Diseases 0.000 description 1
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
• 208000020186 Schizophreniform disease Diseases 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 208000028810 Shared psychotic disease Diseases 0.000 description 1
• 206010040744 Sinus headache Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 206010072005 Spinal pain Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000013200 Stress disease Diseases 0.000 description 1
• 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
• 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 206010043269 Tension headache Diseases 0.000 description 1
• 208000008548 Tension-Type Headache Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 208000001407 Vascular Headaches Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• LMAPGXKIPAIWQA-KRWDZBQOSA-N [3-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]phenyl]methanol Chemical compound OCC1=CC=CC(C=2C(=CC=CC=2)CO[C@@H]2CNCC2)=C1 LMAPGXKIPAIWQA-KRWDZBQOSA-N 0.000 description 1
• COERJHDMQUPDCV-UHFFFAOYSA-N [K].FB(F)F Chemical class [K].FB(F)F COERJHDMQUPDCV-UHFFFAOYSA-N 0.000 description 1
• SAIFTDNQIARTIU-UHFFFAOYSA-N [N].CCC Chemical compound [N].CCC SAIFTDNQIARTIU-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• DPRMFUAMSRXGDE-UHFFFAOYSA-N ac1o530g Chemical compound NCCN.NCCN DPRMFUAMSRXGDE-UHFFFAOYSA-N 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
• 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• 229960004538 alprazolam Drugs 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 229960002519 amoxapine Drugs 0.000 description 1
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
• 201000002426 animal phobia Diseases 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000000010 aprotic solvent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 206010003074 arachnoiditis Diseases 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000021311 artificial sweeteners Nutrition 0.000 description 1
• 150000001543 aryl boronic acids Chemical class 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229960002430 atomoxetine Drugs 0.000 description 1
• 208000025748 atypical depressive disease Diseases 0.000 description 1
• 229960001671 azapropazone Drugs 0.000 description 1
• WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000012455 biphasic mixture Substances 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 208000030963 borderline personality disease Diseases 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229960002729 bromazepam Drugs 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 230000005587 bubbling Effects 0.000 description 1
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
• 229960001058 bupropion Drugs 0.000 description 1
• 229960002495 buspirone Drugs 0.000 description 1
• QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
• JMLFOZVZGFQYOT-UHFFFAOYSA-N butanedioic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)CCC(O)=O JMLFOZVZGFQYOT-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
• 229960000623 carbamazepine Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960004362 clorazepate Drugs 0.000 description 1
• XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
• 208000018912 cluster headache syndrome Diseases 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940029644 cymbalta Drugs 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 229950010286 diolamine Drugs 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 208000035548 disruptive behavior disease Diseases 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 229960001393 dosulepin Drugs 0.000 description 1
• 229960005426 doxepin Drugs 0.000 description 1
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
• 229940098766 effexor Drugs 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 229960004341 escitalopram Drugs 0.000 description 1
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229960004945 etoricoxib Drugs 0.000 description 1
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
• 229950003930 femoxetine Drugs 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 1
• 229950003678 flesinoxan Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
• 229960004038 fluvoxamine Drugs 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229940003380 geodon Drugs 0.000 description 1
• 229960000647 gepirone Drugs 0.000 description 1
• QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229960002158 halazepam Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229950000177 hibenzate Drugs 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 102000055827 human SLC6A2 Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 206010020765 hypersomnia Diseases 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229910052806 inorganic carbonate Inorganic materials 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 238000000752 ionisation method Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960002844 iprindole Drugs 0.000 description 1
• PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
• 229950003599 ipsapirone Drugs 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 229960002672 isocarboxazid Drugs 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• 229940116871 l-lactate Drugs 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 238000011542 limb amputation Methods 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 229960001078 lithium Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 229960002813 lofepramine Drugs 0.000 description 1
• SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
• 229960004391 lorazepam Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 229960002373 loxoprofen Drugs 0.000 description 1
• YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 229960004090 maprotiline Drugs 0.000 description 1
• QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
• 210000004086 maxillary sinus Anatomy 0.000 description 1
• 229960003464 mefenamic acid Drugs 0.000 description 1
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
• 229960003194 meglumine Drugs 0.000 description 1
• 201000003995 melancholia Diseases 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 229960003955 mianserin Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000011812 mixed powder Substances 0.000 description 1
• YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
• 229960004644 moclobemide Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 229940035363 muscle relaxants Drugs 0.000 description 1
• 239000003158 myorelaxant agent Substances 0.000 description 1
• PZEXFDIWYWNGIM-FQEVSTJZSA-N n,n-di(propan-2-yl)-2-[2-[[(3s)-pyrrolidin-3-yl]oxymethyl]phenyl]benzamide Chemical compound CC(C)N(C(C)C)C(=O)C1=CC=CC=C1C1=CC=CC=C1CO[C@@H]1CNCC1 PZEXFDIWYWNGIM-FQEVSTJZSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• AAUXXGQZDXLBMV-UHFFFAOYSA-N n-ethyl-n-[(2-phenylphenyl)methyl]pyrrolidin-3-amine Chemical compound C1CNCC1N(CC)CC1=CC=CC=C1C1=CC=CC=C1 AAUXXGQZDXLBMV-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 208000025319 neurotic depression Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960000965 nimesulide Drugs 0.000 description 1
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229950004864 olamine Drugs 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
• 230000003349 osteoarthritic effect Effects 0.000 description 1
• 229940053544 other antidepressants in atc Drugs 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000005565 oxadiazolylene group Chemical group 0.000 description 1
• 229960004535 oxazepam Drugs 0.000 description 1
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000005564 oxazolylene group Chemical group 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 230000037324 pain perception Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006201 parenteral dosage form Substances 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000008529 pathological progression Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960000964 phenelzine Drugs 0.000 description 1
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229960004856 prazepam Drugs 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 150000004672 propanoic acids Chemical class 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 229960002601 protriptyline Drugs 0.000 description 1
• BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
• 229940035613 prozac Drugs 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000005550 pyrazinylene group Chemical group 0.000 description 1
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000005551 pyridylene group Chemical group 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000005576 pyrimidinylene group Chemical group 0.000 description 1
• NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 150000003873 salicylate salts Chemical class 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 208000012672 seasonal affective disease Diseases 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 229940035004 seroquel Drugs 0.000 description 1
• 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
• 229960000652 sertindole Drugs 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 230000003093 somatogenic effect Effects 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 229940012488 strattera Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 125000005650 substituted phenylene group Chemical group 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000002820 sympathetic nervous system Anatomy 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
• UYEPWCNJSOKBRT-ZDUSSCGKSA-N tert-butyl (3s)-3-[(2-bromo-4-fluorophenyl)methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=CC=C(F)C=C1Br UYEPWCNJSOKBRT-ZDUSSCGKSA-N 0.000 description 1
• QHWGHKCFUZEVFZ-ZDUSSCGKSA-N tert-butyl (3s)-3-[(2-bromo-5-fluorophenyl)methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=CC(F)=CC=C1Br QHWGHKCFUZEVFZ-ZDUSSCGKSA-N 0.000 description 1
• UZXKSONULGWOOP-ZDUSSCGKSA-N tert-butyl (3s)-3-[(2-bromophenyl)methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=CC=CC=C1Br UZXKSONULGWOOP-ZDUSSCGKSA-N 0.000 description 1
• MKBXFLGCUBJBQY-ZDUSSCGKSA-N tert-butyl (3s)-3-[(2-chloro-6-cyanophenyl)methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=C(Cl)C=CC=C1C#N MKBXFLGCUBJBQY-ZDUSSCGKSA-N 0.000 description 1
• VJHSUCUFQSDAOD-INIZCTEOSA-N tert-butyl (3s)-3-[[2-(2,4-difluorophenyl)pyridin-3-yl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=CC=CN=C1C1=CC=C(F)C=C1F VJHSUCUFQSDAOD-INIZCTEOSA-N 0.000 description 1
• SXUXUUFHCRBDTD-HNNXBMFYSA-N tert-butyl (3s)-3-[[3-(2,5-difluorophenyl)pyridin-2-yl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OCC1=NC=CC=C1C1=CC(F)=CC=C1F SXUXUUFHCRBDTD-HNNXBMFYSA-N 0.000 description 1
• LARYGWVELOUTHD-NRFANRHFSA-N tert-butyl (3s)-3-[ethyl-[(2-phenylphenyl)methyl]amino]pyrrolidine-1-carboxylate Chemical compound CCN([C@@H]1CN(CC1)C(=O)OC(C)(C)C)CC1=CC=CC=C1C1=CC=CC=C1 LARYGWVELOUTHD-NRFANRHFSA-N 0.000 description 1
• UZXKSONULGWOOP-UHFFFAOYSA-N tert-butyl 3-[(2-bromophenyl)methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OCC1=CC=CC=C1Br UZXKSONULGWOOP-UHFFFAOYSA-N 0.000 description 1
• VJHSUCUFQSDAOD-UHFFFAOYSA-N tert-butyl 3-[[2-(2,4-difluorophenyl)pyridin-3-yl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OCC1=CC=CN=C1C1=CC=C(F)C=C1F VJHSUCUFQSDAOD-UHFFFAOYSA-N 0.000 description 1
• SXUXUUFHCRBDTD-UHFFFAOYSA-N tert-butyl 3-[[3-(2,5-difluorophenyl)pyridin-2-yl]methoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OCC1=NC=CC=C1C1=CC(F)=CC=C1F SXUXUUFHCRBDTD-UHFFFAOYSA-N 0.000 description 1
• LARYGWVELOUTHD-UHFFFAOYSA-N tert-butyl 3-[ethyl-[(2-phenylphenyl)methyl]amino]pyrrolidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC1N(CC)CC1=CC=CC=C1C1=CC=CC=C1 LARYGWVELOUTHD-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 229960005214 tetrazepam Drugs 0.000 description 1
• IQWYAQCHYZHJOS-UHFFFAOYSA-N tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000005557 thiazolylene group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000005556 thienylene group Chemical group 0.000 description 1
• 125000001583 thiepanyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 125000005503 thioxanyl group Chemical group 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229960004380 tramadol Drugs 0.000 description 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
• 229960003991 trazodone Drugs 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000005558 triazinylene group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 125000005559 triazolylene group Chemical group 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 229960002431 trimipramine Drugs 0.000 description 1
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
• 229960003688 tropisetron Drugs 0.000 description 1
• 231100000691 up-and-down procedure Toxicity 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 229960001255 viloxazine Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 208000009935 visceral pain Diseases 0.000 description 1
• 239000011345 viscous material Substances 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 229950000339 xinafoate Drugs 0.000 description 1
• 229940051225 xyrem Drugs 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1